v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues    
Service $ 115,476 $ 2,938
Product 130,909 168,597
Total Revenues 246,385 171,535
Operating Expenses    
Research and development 2,607,444 4,629,527
General and administrative 2,243,362 2,253,743
Sales and marketing 917,299 1,672,769
Total Operating Expenses 5,768,105 8,556,039
Operating Loss (5,521,720) (8,384,504)
Other Income (Expenses)    
Grant income 121,566 0
Interest income 158 8,654
Interest expense (96,669) (77,233)
Gain (Loss) on change in fair value of warrant liability 20,038 (18,922)
Total Other Income (Expenses) 45,093 (87,501)
Net Loss (5,476,627) (8,472,005)
Net Loss attributable to Non-Controlling Interest 52,868 104,617
Net Loss attributable to VolitionRx Stockholders (5,423,759) (8,367,388)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments (253,929) 15,026
Net Comprehensive Loss $ (5,730,556) $ (8,456,979)
Loss Per Common Share - Attributable to Common Stockholders - Basic and Diluted $ (0.06) $ (0.10)
Weighted Average Shares Outstanding - Basic and Diluted 96,536,052 81,956,660

Source

10-Q PDF
XBRL